Open access
Open access
Powered by Google Translator Translator

Daily Archives: November 7, 2021

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

7 Nov, 2021 | 20:35h | UTC

Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR Study

Commentaries:

Expert reaction to press release from Pfizer giving interim analysis of their Phase 2/3 EPIC-HR study of PAXLOVID™ in non-hospitalized high-risk adults with COVID-19 – Science Media Centre

Pfizer’s Good News Is the World’s Good News – Science

Experimental Pfizer pill prevents Covid hospitalizations and deaths – STAT

Pfizer Says New Anti-Viral Drug Combination Cuts Risks Of Serious COVID-19 By 89% – Health Policy Watch

Pfizer reports good results against severe COVID-19 for its antiviral pill – CIDRAP

Covid: Pfizer says antiviral pill 89% effective in high-risk cases – BBC

Pfizer says COVID-19 pill cut hospital, death risk by 90% – Associated Press

Pfizer’s COVID-19 pill treatment reduces risk of being hospitalized or dying by 89%, company says – ABC News

 

Commentary on Twitter (thread – click for more)

 

Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination.

7 Nov, 2021 | 20:29h | UTC

Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination – Clinical Infectious Diseases

Related:

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Viewpoint | Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know.

7 Nov, 2021 | 20:31h | UTC

Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know – JAMA

 

Viewpoint | Children and COVID-19 in schools.

7 Nov, 2021 | 20:24h | UTC

Children and COVID-19 in schools – Science

Related:

Instead of quarantine for Covid-exposed students, some schools are trying test-to-stay.

Cluster RCT: Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission.

Kids are losing school days to quarantines. Here’s a way to keep them in classrooms – “Test-to-stay could dramatically reduce close contact quarantines”.

Opinion | Data from routine Covid testing can help schools stay open this year.

CDC Report: Schools without mask requirements were more likely to have Covid-19 outbreaks.

Perspective | Schools have begun mass testing for COVID-19. But hurdles and uncertainties remain.

COVID and schools: the evidence for reopening safely.

COVID studies note online learning stress, fewer cases in schools with protocols

 

[Not published yet] Chinese drug firm Sinovac says Covid-19 vaccine safe for children and babies as young as six months old.

7 Nov, 2021 | 20:32h | UTC

Chinese drug firm Sinovac says Covid-19 vaccine safe for children, babies as young as six months old; submits data to Hong Kong government – South China Morning Post

Related:

Randomized phase 1/2 trial: Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in children and adolescents aged 3–17 years.

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

 

COVID-19 vaccination in pregnancy, pediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety.

7 Nov, 2021 | 20:27h | UTC

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety – Drug Safety

 

RCT: In patients with chronic kidney diseases and anemia undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa to increase hemoglobin levels and regarding cardiovascular outcomes.

7 Nov, 2021 | 20:18h | UTC

Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Oral pill as safe, efficacious as conventional treatment for anemia in patients with kidney disease – Brigham and Women’s Hospital

 

Commentary on Twitter

 

Germany offers booster shots to everyone amid ‘very worrying’ surge in cases.

7 Nov, 2021 | 20:22h | UTC

Germany offers booster shots to everyone amid ‘very worrying’ surge in cases – CNN

 

RCT: In patients with chronic kidney diseases and anemia not undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa in increasing hemoglobin levels and regarding cardiovascular outcomes.

7 Nov, 2021 | 20:17h | UTC

Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Oral pill as safe, efficacious as conventional treatment for anemia in patients with kidney disease – Brigham and Women’s Hospital

 

Commentary on Twitter

 

Among patients with atrial fibrillation, 4-year outcomes of PRAGUE-17 randomized trial showed that left atrial appendage closure was noninferior to non-warfarin oral anticoagulation for preventing net ischemic and bleeding events.

7 Nov, 2021 | 20:15h | UTC

Left Atrial Appendage Closure versus Non-Warfarin Oral Anticoagulation in Atrial Fibrillation: 4-Year Outcomes of PRAGUE-17 – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Commentaries:

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term – TCTMD

PRAGUE-17: LAAC Noninferior to NOACs For Major AFib-Related CV, Neurological Events Longer-Term – American College of Cardiology

Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-Risk Atrial Fibrillation Patients – PRAGUE-17 – American College of Cardiology

 

Commentary on Twitter

 

RCT: In patients with advanced chronic kidney disease and poorly controlled hypertension, Chlortalidone had a significant impact in blood-pressure control (−11.0 mm Hg vs. −0.5 mm Hg in the placebo group).

7 Nov, 2021 | 20:20h | UTC

Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Cheap Diuretic, Chlorthalidone, Drops BP in Advanced Kidney Disease – Medscape (free registration required)

 

Commentary on Twitter

 

New study challenges the idea that a coronary artery calcium score of 0 is enough for ruling out coronary stenosis in symptomatic patients, especially in young adults.

7 Nov, 2021 | 20:09h | UTC

Association of Age With the Diagnostic Value of Coronary Artery Calcium Score for Ruling Out Coronary Stenosis in Symptomatic Patients – JAMA Cardiology (link to abstract – $ for full-text)

Commentary: Zero CAC Questionable for Ruling Out Obstructive CAD in Young Adults – TCTMD

 

Commentary from the author on Twitter (thread – click for more)

 

Mapping conflict of interests: scoping review.

7 Nov, 2021 | 20:10h | UTC

Mapping conflict of interests: scoping review – The BMJ

Press release: Study reveals “extensive network” of industry ties with healthcare – BMJ

 

NICE draft guideline recommends SGLT2 inhibitor dapagliflozin for some patients with chronic kidney disease.

7 Nov, 2021 | 20:14h | UTC

NICE recommend dapagliflozin for people with chronic kidney disease – National Institute for Health and Care Excellence

See draft guideline:

Appraisal consultation document (online commenting)

Appraisal consultation document (PDF version)

Related:

NICE Guideline: Assessment and management of chronic kidney disease.

Secondary analysis of RCT finds Dapagliflozin is safe for patients with stage 4 chronic kidney disease.

Randomized trial: Dapagliflozin in patients with chronic kidney disease

 

A cohort study with 287 patients showed that those who fulfill 5 criteria 2 or 3 days after laparoscopic colorectal surgery (a CRP below 150 mg/dL, a return of bowel function, tolerance of a diet, little pain, and afebrile during the entire stay) have a low risk of developing an anastomotic leak. These criteria have the potential to allow for safe early discharge.

7 Nov, 2021 | 20:06h | UTC

Assessing Criteria for a Safe Early Discharge After Laparoscopic Colorectal Surgery – JAMA Surgery (free for a limited period)

 

Commentary on Twitter

 

M-A: Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer.

7 Nov, 2021 | 20:07h | UTC

Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis – EClinicalMedicine

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.